South Africa Stem Cell Therapy Market Industry Trends and Forecast to 2034: Segmented by (Cell Type, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
South Africa · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$17.8 MnPlaceholder estimate
Estimate 2025$20.8 Mn0.6% of the global market
Projected 2034$82.9 Mn 298.4%Adds $62.1 Mn over 9 forecast years
CAGR 2025–203416.6%Faster than 78% of 180 Pharmaceuticals markets here
Key players5
South Africa is 0.63% of the global market.
In Africa, the largest is South Africa (this report) at $20.8 Mn.
2 in South AfricaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The South Africa Stem Cell Therapy Market Analysis Executive Summary
Stem cell therapies use stem cells to repair or replace damaged tissue, for blood disorders, joints, heart and nerve conditions.
Key segments of the stem Cell Therapy market include cell type (Mesenchymal Stem Cells, Hematopoietic Stem Cells and Induced Pluripotent Stem Cells) and indication (Musculoskeletal, Cardiovascular and Neurological).
South Africa Stem Cell Therapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
South Africa Stem Cell Therapy Market Dynamics
Market Growth Drivers
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the stem Cell Therapy market.
Opportunity
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the stem Cell Therapy market.
Market Restraints
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the stem Cell Therapy market. Payers are still working out how to pay for one-time cures.
Competitive Landscape for Stem Cell Therapy Market in South Africa
The stem Cell Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Stem Cell Therapy Market in South Africa
Stem Cell Therapy in South Africa: rules, payment and research
The South African Health Products Regulatory Authority (SAHPRA) registers medicines.[1] Most people use public health services and a minority belong to private medical schemes; the National Health Insurance Act, signed in May 2024, plans to fund care for everyone.[2] ClinicalTrials.gov lists 2 studies on Stem Cell Therapy that are recruiting, active or about to start in South Africa.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for stem Cell Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in South Africa.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Cell Type
4.2 By Indication
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Mesoblast
7.2 Vertex Pharmaceuticals
7.3 Takeda
7.4 Pluri
7.5 BlueRock Therapeutics (Bayer)
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The stem Cell Therapy market can be segmented based on various criteria, including cell type, indication and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Stem Cell Therapy right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Stem Cell Therapy in context
South Africa compared
Health spending per person: 537 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 17 countries we cover in Africa.[1]
Doctors: 0.79 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 17 countries we cover in Africa.[2]
People aged 65 and over: 6.9% of people (2025). World: 10.4% of people (2025). 2nd highest of the 17 countries we cover in Africa.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.
How big is the Stem Cell Therapy market in South Africa?
Placeholder estimate: about $20.8 Mn in 2025, rising to about $82.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Stem Cell Therapy market in South Africa growing?
Placeholder estimate: about 16.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Stem Cell Therapy market report cover?
The report splits the market by cell type (Mesenchymal Stem Cells, Hematopoietic Stem Cells, Induced Pluripotent Stem Cells), indication (Musculoskeletal, Cardiovascular, Neurological, Blood Disorders) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Stem Cell Therapy market?
Key players include Mesoblast, Vertex Pharmaceuticals, Takeda Pharmaceutical Company Ltd, Pluri and BlueRock Therapeutics (Bayer).
What is driving the Stem Cell Therapy market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the stem Cell Therapy market.
Most people use public health services and a minority belong to private medical schemes; the National Health Insurance Act, signed in May 2024, plans to fund care for everyone. Source: National Department of Health. Checked 14 Nov 2026.
How many clinical trials on Stem Cell Therapy are running in South Africa?
2 studies are recruiting, active or about to start in South Africa, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.
How much research is published on Stem Cell Therapy?
PubMed lists 4,354 papers on Stem Cell Therapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.